SpringerLink
Log in

Immunomodulation and Therapeutic Effects of a Monotherapy with Interleukin-2 as an Induction Therapy in Patients with Poor-Prognosis Acute Myeloid Leukemia

  • Conference paper
Acute Leukemias VII

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 39))

  • 138 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 67.40
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Wiernik PH, Dutcher P, Todd M, Caliendo G, Benson L (1994) Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 47 (1): 41–44

    Article  PubMed  CAS  Google Scholar 

  2. Lauria F, Raspadori D, Rondelli D, Ventura MA, Foa R (1994) In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 8 (5): 724–728

    PubMed  CAS  Google Scholar 

  3. Lotzova E, Savary CA (1993) Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts. Med Oncol Tumor Pharmacother 10 (1–2): 13–19

    PubMed  CAS  Google Scholar 

  4. Mandelli F, Vignetti M, Tosti S, Andrizzi C, Foa R, Meloni G (1993) Interleukin 2 treatment in acute myelogenous leukemia. Stem Cells Dayt 11 (4): 263–268

    Article  PubMed  CAS  Google Scholar 

  5. Klingemann HG, Neerunjun J, Schwulera U, Ziltener HJ (1993) Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production. Leukemia 7 (9): 1389–1393

    PubMed  CAS  Google Scholar 

  6. Klingemann HG, Deal H, Reid D, Eaves CJ (1993) Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21 (9): 1263–1270

    PubMed  CAS  Google Scholar 

  7. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi-L, Collis C (1993) Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11 (5): 399–401

    CAS  Google Scholar 

  8. Fefer A, Benyunes M, Higuchi C, York A, Massumoto C, Lindgren C, Buckner CD, Thompson JA (1993) Interleukin-2 ± lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 89 Suppl 1: 2–7

    Article  Google Scholar 

  9. Prentice HG, Macdonald ID, Hamon MD (1993) The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allo-geneic bone marrow transplantation to the application of interleukin 2. Cancer Treat Res 64: 121–134

    Article  PubMed  CAS  Google Scholar 

  10. Olive D, Lopez M, Blaise D, Viens P, Stoppa AM, Brandely M, Mawas C, Mannoni P, Maraninchi D (1991) Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2. J Immunother 10 (6): 412–417

    Article  PubMed  CAS  Google Scholar 

  11. Verdonck LF, Heugten HG van, Giltay J, Franks CR (1991) Amplification of the graft-versusleukemia effect in man by interleukin-2. Transplantation 51 (5): 1120–1124

    Article  PubMed  CAS  Google Scholar 

  12. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK (1991) Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc 23 (1 Pt2): 1704–1705

    PubMed  CAS  Google Scholar 

  13. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A (1990) Bone marrow transplantation with interleukin-2-activated bone marrow fol-lowed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76 (11): 2187–2190

    PubMed  CAS  Google Scholar 

  14. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK (1989) Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 74 (7): 2335–2342

    PubMed  CAS  Google Scholar 

  15. Sykes M, Harty MW, Szot GL, Pearson DA (1994) Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83 (9): 2560–2569

    PubMed  CAS  Google Scholar 

  16. Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Loffler H, Muller-Ruchholtz W (1993) Natural killer cells as effector cells of graft-versusleukemia activity in a murine transplantation model. Bone Marrow Transplant 12 Suppl 3: S57–60

    Google Scholar 

  17. Sykes M, Harty MW, Pearson DA (1994) Strain dependence of interleukin-2-induced graft-versus-host disease protection: evidence that interleukin-2 inhibits selected CD4 functions. J Immunother 15 (1): 11–21

    Article  CAS  Google Scholar 

  18. Klingemann HG, Neerunjun J, Schwulera U, Ziltener HI (1993) Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production. Leukemia 7 (9): 1389–1393

    PubMed  CAS  Google Scholar 

  19. Sykes M, Abraham VS, Harty MW, Pearson DA (1993) IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150 (1): 197–205

    PubMed  CAS  Google Scholar 

  20. Klingemann HG (1992) Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies. Leuk Lymphoma 8 (6): 421–429

    Article  PubMed  CAS  Google Scholar 

  21. Klingemann HG, Phillips GL (1991) Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8 (2): 73–81

    PubMed  CAS  Google Scholar 

  22. Verdonck LF, Heugten HG van, Giltay J, Franks CR (1991) Amplification of the graft-versusleukemia effect in man by interleukin-2. Transplantation 51 (5): 1120–1124

    Article  PubMed  CAS  Google Scholar 

  23. Lotzova E (1984) The role of natural killer cells in immune surveillance against malignancies. Cancer Bull 36: 215–217

    Google Scholar 

  24. Lotzova E, McCredie KB, Muesse L (1979) Natural killer cells in man: Their possible involvement in leukemia and bone marrow transplantation. In: Baum SJ, Ledney GD (eds) Experimental Hematology Today. Springer, New York, pp 207–215

    Google Scholar 

  25. Lotzova E, Savary CA, Keating MJ (1982) Studies on the mechanism of defective natural killing in leukemia-diseased patients. Exp Hematol 10: 83–89

    Google Scholar 

  26. Pollak SB (1983) In vivo functions of natura killer cells. Sury Synth Pathol Res 2: 93–98

    Google Scholar 

  27. Herbermann RB, Ortaldo JR (1981) Natural killer cells: their role in defenses against disease. Science 214: 24–27

    Article  Google Scholar 

  28. Lotzova E, Savary CA, Herbermann RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138: 2718–2727

    PubMed  CAS  Google Scholar 

  29. Dutcher JP, Wiernik PH, Todd M (1993) Interleukin-2 as maintenance therapy for acute Inyelogenous leukemia in second remission. Dermatol 21: 1048 (abstr)

    Google Scholar 

  30. Golumbek P, Levitsky H, Jaffee L, Pardoll DM (1993) The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol Res 12 (2): 183–192

    Article  PubMed  CAS  Google Scholar 

  31. Whittington R, Faulds D (1993) Interleukin-2.A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46 (3): 446–514

    Article  PubMed  CAS  Google Scholar 

  32. Yarbro JW, Bornstein RS, Mastrangelo MJ (eds) (1993) Interleukin-2: Advances in clinical research and treatment. Sem Oncol Vol 20, No 6, Suppl 9

    Google Scholar 

  33. Rosenberg SA (1992) The Immunotherapy and gene therapy of cancer. Kamofsky memorial lecture. J Clin Oncol 10 (2): 180–199

    PubMed  CAS  Google Scholar 

  34. Rosenberg SA, Longo DL, Lotze MT (1989) Principles and applications of biologic therapy. In: De-Vita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology, ed 3. Lippincott, Philadelphia, pp 1342–1398

    Google Scholar 

  35. Parkinson DB, Lotzova E (1990) Interleukin-2, killer cells and cancer therapy: An overview. Nat Immun Cell Growth Regul 9: 237–241

    PubMed  CAS  Google Scholar 

  36. Parkinson DB (1990) Lessons from the clinical trials of Interleukin-2. Nat Immun Cell Growth Regul 9: 242–252

    PubMed  CAS  Google Scholar 

  37. Foa R, Guanni A, Gansbacher B (1992) IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 66 (6): 992–998

    Article  PubMed  CAS  Google Scholar 

  38. Lindemann A, Brossart P, Höffken K, Flaßhove M, Voliotis D, Diehl V, Hecker G, Wagner H, Mertelsmann R (1993) Immunmodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother 37: 307–315

    Article  PubMed  CAS  Google Scholar 

  39. Schneekloth C, Körfer A, Hadam M, Hänninen EL, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J (1993) Low-Dose Interleukin-2 in combination with Interferon-a effectively modulates biological response in vitro. Acta Haematol 89: 13–21

    Article  PubMed  CAS  Google Scholar 

  40. Fiorentino B, Di Stefano P, Giulinani C, Amatteti C, Tinari N, Natoli C, Garufi C, Iacobelli S (1992) Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. Br J Cancer 66: 981–983

    Article  PubMed  CAS  Google Scholar 

  41. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant Interleukin 2. J Clin Invest Vol 91: 123–132

    Article  PubMed  CAS  Google Scholar 

  42. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C, Roy SE, Shearer RJ, Marsden RA, Bevan D, Gordon-Smith EC, Coombes RC (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 63: 275–278

    Article  PubMed  CAS  Google Scholar 

  43. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perlilo D, Smith K, Ritz J (1991) Extended continuous infusion low-dose recombinant Interleukin-2 in advanced cancer: prolonged Immunomodulation without significant toxicity. J Clin Oncol Vo19, No 12: 2110–2119

    Google Scholar 

  44. Foa R, Guanni A, Gansbacher B (1992) IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 66 (6): 992–998

    Article  PubMed  CAS  Google Scholar 

  45. Kintzel PE, Calis KA (1991) Recombinant Interleukin-2, a biological response modifier. Clin Pharm Vol 10: 110–128

    PubMed  CAS  Google Scholar 

  46. Smith KA (1993) Lowest dose Interleukin-2 Immunotherapy. Blood Vol 81, No 6: 1414–1423

    PubMed  CAS  Google Scholar 

  47. Foa R, Meloni G, Tosti S, Meloni G, Gavosto F, Mandelli F (1990) Induction and persistance of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant Interleukin-2. Leuk Lymph 1: 113

    Article  Google Scholar 

  48. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F (1991) Treatment of acute myeloid leukemia patients with interleukin 2: a pilot study. Br J Haematol 77: 491

    Article  PubMed  CAS  Google Scholar 

  49. Lim SH, Newland AC, Kelsey S, Bell A, Offer-mann E, Rist C, Gozzard D, Bareford D, Smith MP, Goldstone AH (1992) Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukemia-A phase II study. Cancer Immunol Immunother 34: 337

    Article  PubMed  CAS  Google Scholar 

  50. Maranchini D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, Gratecos N, Bertau-Perez P, Manoni P, Mawas C, Hercend T, Sebahoun G, Carcassone Y (1991) High-dose recombinant interleukin-2 and acute myeloid leukemia in relapse. Blood 78: 2182

    Google Scholar 

  51. Foa M, Fierro TM, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F (1991) Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78: 1041–1046

    PubMed  CAS  Google Scholar 

  52. Lotzova E, Savary CA, Herberman RB (1986) Impaired NK cell profile in leukemia patients. In: Lotzova E, Herbermann RB (eds) Immunob-iology of Natural Killer Cells (vol 2 ). Karger, Basel, Switzerland, p 29

    Google Scholar 

  53. Lotzova E, Savary CA, Keating MI, Hester JP (1985) Defective NK cell mechanism in patients with leukemia. In: Herbermann RB, Callewaert D (eds) Mechanism for cytotoxicity by NK cells. Academic, San Diego, p 507

    Google Scholar 

  54. Adler A, Chervenik PA, Whiteside TL, Lotzova E, Herbermann RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic I for Internal Medicine, University of Cologne, 50924, Köln, Germany

    D. L. Voliotis, S. Schmitz, P. Staib, H. Tesch & V. Diehl

Authors
  1. D. L. Voliotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Staib
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Tesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany

    W. Hiddemann  & B. Wörmann  & 

  2. Department of Internal Medicine, USA

    T. Büchner

  3. Department of Pediatrics, University of Münster, Albert-Schweitzer-Straße 33, 48149, Münster, Germany

    J. Ritter  & U. Creutzig  & 

  4. Dept. of Hematology, University of Texas, Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Tx., USA

    M. Keating MD PhD  & W. Plunkett MD PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Voliotis, D.L., Schmitz, S., Staib, P., Tesch, H., Diehl, V. (1998). Immunomodulation and Therapeutic Effects of a Monotherapy with Interleukin-2 as an Induction Therapy in Patients with Poor-Prognosis Acute Myeloid Leukemia. In: Hiddemann, W., et al. Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71960-8_135

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71960-8_135

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71962-2

  • Online ISBN: 978-3-642-71960-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation